{
  "source": "PubMed",
  "query": "lignans",
  "title": "Unveiling p65 as the target of diphyllin in ameliorating metabolic dysfunction-associated steatotic liver disease via targeted protein degradation technology.",
  "abstract": "Metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by hepatic steatosis, inflammation and fibrosis, is becoming a global epidemic. However, the currently available effective clinical strategies remain limited.",
  "publication_date": "2025-04-28",
  "journal": "Frontiers in pharmacology",
  "doi": "10.3389/fphar.2025.1567639"
}